AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01902823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Services from a Nurse Navigator
Description: Services from a Nurse Navigator
Study NCT01282632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Risperidone will commence at 0.5 mg per day in a single daily dose given once in the evening. Clinicians will have the option, at each visit of increasing the risperidone dose to a maximum of 3 mg/day based on subject response and tolerability (please see Titration Recommendations below).
Study NCT01282632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine will commence at 2.5 mg per day in a single daily dose given once in the evening. Clinicians will have the option, at each visit, of increasing the olanzapine dose to a maximum of 15 mg/day based on subject response and tolerability.
Study NCT01202851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study.
Study NCT01202851 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study.
Study NCT02683915 — intervention group
Intervention type: PROCEDURE
Intervention: Therapeutic hypothermia
Description: Infants in cooled group will be fitted a cooling cap (Olympic Medical Cool Care System, Olympic Medical) around the head for 72 h. infants will be nursed under a radiant overhead heater, which is servo-controlled to the infant's abdominal skin temperature and adjusted to maintain the rectal temperature at 33.5-34.5ºC. At the end of the 72 h cooling period, the infants will be slowly rewarmed at no more than 0•5ºC /h until their temperature become within normal temperature range (36.5-37.5ºC).
Study NCT04426123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Intramuscular injection with Botulinum toxin type A in m.masseter and m.temporalis.
Study NCT04426123 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: Intramuscular injection with NaCl in m.masseter and m.temporalis.
Study NCT03839147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and counseling
Description: After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale were applied to both groups by face to face interview during the day giving appointment for HSG. Immediately after the questionnaires were answered, individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. In addition, the education and counseling given to the participants by the researcher was repeated briefly on the morning of the HSG procedure and any questions of the patients were answered.
Study NCT01452126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine concentration
Description: Single shot preoperative perineural injection of ropivacaine to achieve surgical anesthesia. The concentration of ropivacaine is lowered by 0.05% after every successful surgical anesthesia specific to that block and raised by 0.05% after every unsuccessful surgical anesthesia specific to that block
Study NCT01233947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFP464
Description: AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycle
Study NCT01233947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFP464 + Faslodex
Description: AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycles and faslodex administered per the package label
Study NCT01516372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn 1200mg
Description: 1200 mg of Gen administered as a single dose
Study NCT01516372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gen 6000 mg
Description: 6000 mg of Gen administered as a single dose
Study NCT01516372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn Placebo
Description: Placebo to match GEn Tablets
Study NCT01516372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Placebo to match Moxifloxacin
Study NCT01516372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 400 mg Moxifloxacin administered as a single dose
Study NCT03127930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Participants receive 5 individualized contacts (home visits and phone calls) with either a social worker or a nurse to develop problem solving skills as applied to medication management.
Study NCT04502914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open-to-air strategy
Description: In open-to-air management, the wound will be washed with a chlorhexidine solution and leave the wound open, or portion of the wound assigned to OTA, to the environment. An electric heat lamp (model no. 53103, 250W, Brandt Industries LLC, Bronx, NY) will be placed at as close to 1 yard (0.91 m) as possible from the wound after daily wound care for 24 hours (+/- 6 hours) to promote drying. However, to prevent excessive drying an hourly spritz of topical solution, e.g., DuoDERM® Hydroactive® gel (ConvaTec Oklahoma City, OK) will be used at the bedside.
Study NCT04031378 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Single Dose Radiotherapy (24 Gy) to all detectable lesions, followed by observation
Description: SBRT to a single dose of 24 Gy to up to 3 sites
Study NCT04031378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Dose Radiotherapy (24 Gy) to all detectable lesions followed by adjuvant systemic therapy for 6 months
Description: SBRT 24 Gy to up to 3 nsites, followed by by systemic therapy based on phenotype.
Study NCT04502914 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional closed-wound management
Description: In traditional closed-wound management, once a day the wound will be washed with a chlorhexidine solution and closed with a non-adherent dressing such as ADAPTIC® (Acelity, San Antonio, TX) soaked in topical antimicrobial solutions, ointments, and creams designed to promote wound healing.
Study NCT00875446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo
Study NCT00875446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1223249
Description: I.V Infusion
Study NCT02852330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SA16 research software
Description: Software for measurement of voltage tomography intraoperatively.
Study NCT02852330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CS19 (1.6.2)
Description: Software for measurement of voltage tomography post-operatively.
Study NCT01448642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin loading dose of 80mg before PCI, reloading dose of 80mg 24 hours after PCI, and atorvastatin 40mg for 30 days
Study NCT01448642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo before PCI and 24 hours after PCI. Atorvastatin 40mg for 30 days
Study NCT04333550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine
Description: Intravenous infusion of Deferoxamine
Study NCT00821106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right radial
Description: diagnostic or interventional procedures performed through right transradial approach
Study NCT00821106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: left radial
Description: diagnostic or interventional procedures performed through left transradial approach
Study NCT03629431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic non-invasive ventilation
Description: The sessions of NIV last 1 hour and are repeated every 2 to 3 hours with a goal of a daily assistance period of 6 to 8 hours for a minimum of 24 hours.~The sessions are spaced by periods of unassisted ventilation of 2 hours allowing the patient to rest, feed, receive care including physiotherapy sessions.
Study NCT03629431 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: postoperative standard care
Description: Standard care received postoperatively
Study NCT03258931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib
Description: Crenolanib will be administered orally
Study NCT03258931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midostaurin
Description: Midostaurin will be administered orally
Study NCT03258931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg/m² IV continuous infusion over 24 hours
Study NCT03258931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: 100 mg/m² IV continuous infusion over 24 hours
Study NCT03258931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duanorubicin
Description: 90 mg/m2 IV
Study NCT03258931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duanorubicin
Description: 90 mg/m2 IV
Study NCT02678975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Disulfiram 400 mg daily
Study NCT02678975 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Copper
Description: nutritional supplement with copper, 2 mg daily
Study NCT01588145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM61713
Description: BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
Study NCT00718432 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and nutritional integrated care
Description: Besides the information sharing and the educational booklets, the ENIC group subjects are invited to take a structured exercise course at the participating hospital 3 times a week for 3 months. (twice a week for 24 weeks in 2009 study) The exercise program included warm up; a range of motion, stretching, and postural-correction activities; aerobic strengthening; balance; and cool down. The research team also inquired about the subjects' dietary compliance and responded to their dietary questions during the exercise sessions.
Study NCT00718432 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care with education
Description: The study educational booklet (plus CD-ROM in 2009 study) on frailty, depression, osteoporosis, healthy diets, exercise protocols, and coping strategies are given to the participants. UC group subjects will receive a 2-hour education based on the content of study booklet including 1-hour demonstration of study exercise program in 2009 study. Subjects are contacted monthly (bimonthly in 2009 study ) for frequencies of reading this booklet and the compliance on the suggested diet and exercise protocols. Subjects are also encouraged to follow with their primary care physicians for abnormal results identified from our assessments.
Study NCT00718432 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem solving therapy (PST) integrated care
Description: Besides the information sharing and the educational booklets, the PSTIC group subjects will receive 6 sessions of PST (within 12 weeks in pilot study, within 24 weeks in 2009 study) aiming at solving the 'here-and-now' problems contributing to their mood-related condition and helps increase their self-efficacy. If major depressions are found, subjects are referred to their primary care physicians for further medical managements.
Study NCT03841409 — intervention group
Intervention type: OTHER
Intervention: Collection of blood samples
Description: Nine blood samples will be collected to determine bupivacaine pharmacokinetics at T10min, T20min, T30min, T45min, T60min, T90min, T120min, T180min, and T240min. T0 will be defined as the end of bupivacaine injection.
Study NCT01675947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Immunosuppressive agent. Blocks the T-lymphocyte activation and smooth muscle and endothelial cell proliferation that occurs in response to antigenic and cytokine (interleukin IL-2, IL-4 and IL-15) stimulation through either Ca2+-dependent or Ca2+-independent pathways. Sirolimus arrests cell cycle progression by direct interaction with two intracellular proteins (immunophilin FK binding protein 12 (FKBP-12) and the mammalian target of rapamycin (mTOR), a multifunctional serine-threonine kinase). In cells, sirolimus binds to FKBP-12, and the resulting sirolimus-FKBP-12 complex then binds to and inhibits mTOR.
Study NCT01675947 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine 2%
Study NCT02643485 — intervention group
Intervention type: PROCEDURE
Intervention: Forefoot surgery
Description: Forefoot surgery (Chevron, Scarf, Lapidus, Arthrodesis)
Study NCT01622478 — intervention group
Intervention type: PROCEDURE
Intervention: Sentinel lymph node biopsy
Description: Sentinel lymph node biopsy after neoadjuvant chemotherapy for the patients with clinically positive-nodes at presentation
Study NCT01622478 — intervention group
Intervention type: DRUG
Intervention: Neoadjuvant chemotherapy
Description: Neoadjuvant chemotherapy for breast cancer patients with clinically positive-node at initial diagnosis
Study NCT01622478 — intervention group
Intervention type: PROCEDURE
Intervention: complete axillary lymph node dissection
Description: Complete axillary lymph node dissection after sentinel node biopsy for estimation of false-negative rate of sentinel node biopsy
Study NCT01622478 — intervention group
Intervention type: PROCEDURE
Intervention: positron emission tomography and ultrasonogram
Description: Routine evaluation of axillary nodal status using 18-fluorodeoxyglucose positron emission tomography and ultrasonogram before and after chemotherapy
Study NCT03577457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin nasal spray
Description: intranasal administration of oxytocin (24 IU)
Study NCT03577457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATD treatment
Description: oral administration of ATD (75.2g) (Acute Tryptophan Depletion)
Study NCT01202851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva Testing
Description: 4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
Study NCT01202851 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Saliva Testing
Description: 4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
Study NCT00062062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00062062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Study NCT02678975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alkylating Agents
Description: Alkylating antineoplastic agent
Study NCT02678975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alkylating Agents
Description: Alkylating antineoplastic agent
Study NCT05058235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Release Technique
Description: Moist Hot pack 10 mins/1 set/ (6 days/ week), TENS 20 mins/1 set/ (6 days/ week), Quadriceps Isometric Strengthening 5 sec hold, 10 reps/ 1 set/(6 days/ week), Active release Technique 5 reps/ 1 set/ (6 days/ week)~A total of 2 weeks (12 sessions, 6 sessions/ week) were given each consisting of 40 mins.
Study NCT05058235 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bent leg raise
Description: Moist Hot pack 10 mins/1 set/ (6 days/ week), TENS 20 mins/1 set/ (6 days/ week), Quadriceps Isometric Strengthening 5 sec hold, 10 reps/ 1 set/(6 days/ week), Bent leg raise 5 sec hold/ 5 sec stretch/ 3 reps/ 1 min rest interval/ 1 set/ (6 days/ week).~A total of 2 weeks (12 sessions, 6 sessions/ week) were given each consisting of 40 mins.
Study NCT03681665 — intervention group
Intervention type: OTHER
Intervention: ultralow dose abdominopelvic CT
Description: In the patient cohort with abdominal abscess, ultralow dose abdominopelvic CT will be performed as a follow-up protocol. Ultralow dose CT has approximately 80\~90% reduced radiation dose compared to standard dose CT.
Study NCT01705730 — intervention group
Intervention type: DRUG
Intervention: tocilizumab
Description: Participants received tocilizumab monotherapy according to individualized physician-prescribed regimens.
Study NCT00515489 — intervention group
Intervention type: DRUG
Intervention: Risperidone
Description: as prescribed
Study NCT02027961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intravenous dose of 3 or 10 mg/kg durvalumab.
Study NCT02027961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Oral dose of 150 mg dabrafenib capsule.
Study NCT02027961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Oral dose of 2 mg trametinib tablet.
Study NCT05521620 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The father-friendly NICU
Description: * Fathers have skin-to-skin contact with their infants~* Fathers participate in important situations~* Fathers receive information and guidance directly~* Both parents participate in meaningful conversations~* The department organize mother and father groups~* The families have the opportunity to have a close family member to support them~* Older siblings have the opportunity to stay overnight.~* The department offer counseling by a social worker
Study NCT00142935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-release Initiation of MMT
Description: Participants assigned to arm 1 will undergo extensive assessment (physical, medical history, drug use and treatment history) prior to initiating treatment. MMT will begin 1-30 days prior to release from incarceration. MMT first dose will begin at 5 mg with 2 mg increase per day until release or therapeutic dose of 60-120 mg is achieved. Daily observation by dosing nurses and twice weekly symptom review by Research Assistant will occur. Additionally, participants assigned to Arm 1 will have all logistical arrangements made for entry into a community methadone clinic program within 24 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
Study NCT00142935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post Release Initiation of MMT.
Description: Participants assigned to Arm 2 will have all logistical arrangements made for entry into a community methadone clinic program within 24-48 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
Study NCT00142935 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Plus
Description: Participants assigned to Arm 3 will not begin treatment prior to release from incarceration or have treatment paid for by the study. However, study staff will work with participants to identify ways to pay for treatment, including assisting with medicaid applications, etc. Further, the study will make the logistical arrangements for entering treatment if participant has a means to finance MMT.
Study NCT00062062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT03333655 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Description: Participants who received or are receiving CPI therapy for metastatic cancer or hematologic malignancies.
Study NCT02701361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile mindfulness
Description: Receives audiovisual mindfulness content via internet plus call depending on symptoms or request.
Study NCT02701361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard mindfulness
Description: Receives weekly calls from mindfulness expert for 4 weeks.
Study NCT02701361 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: education
Description: Receives web-based content about critical illness topics. Also receives two calls from study team to describe materials and answer questions about materials.
Study NCT04591301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HEC113995 PA•H2O tablets
Description: Each dose of HEC113995 PA•H2O tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
Study NCT04591301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC113995 PA•H2O tablets
Description: Each dose of HEC113995 PA•H2O tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
Study NCT04591301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: Placebo tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
Study NCT04898803 — intervention group
Intervention type: OTHER
Intervention: conventional DGVS training
Description: see above
Study NCT04898803 — intervention group
Intervention type: OTHER
Intervention: extended simulator training
Description: see above
Study NCT03370055 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: LeucoPatch®
Description: LeucoPatch® is an elastic membrane produced by the patients own venous blood by centrifugation, and one or two is placed on the wound once a week The LeucoPatch® consist of the fibrin Leucocytes and growth factors from the patients own blood